EydisBio is an innovative early-stage pharmaceutical company dedicated to the discovery and development of novel, highly selective small molecule therapeutics. Our pioneering, potentially first-in-class TAK1 inhibitor program has demonstrated significant promise in preclinical models of various autoimmune and inflammatory diseases, and has the potential to deliver safer and more effective treatment options for patients suffering from these debilitating conditions.


Industries
Biotechnology
Chemical
Health
Health Care & Hospitals
Medical Pharmaceuticals
Pharmaceuticals

Contact Information
Robert Freeze
Vice President of Business Development
(919) 909-2237
[email protected]

Latest

Oct 23, 2024, 11:37 ET EydisBio Awarded $0.5 Million Grant to Advance TAK1 Inhibitor Program for Alzheimer's Disease

EydisBio, an innovative pharmaceutical company dedicated to developing novel treatments for various autoimmune and inflammatory diseases, is excited...

Sep 25, 2024, 11:37 ET EydisBio Receives FDA Orphan Drug Designation for TAK1 Inhibitor for the Treatment of Systemic Sclerosis

EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly...

Aug 28, 2024, 11:37 ET EydisBio Awarded $2.6 Million Grant to Advance TAK1 Inhibitor Program for Systemic Sclerosis

EydisBio, an early-stage pharmaceutical company leveraging a novel approach to treating various autoimmune and inflammatory diseases, is thrilled to...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE